(Lymphoma) FDA Approves Brukinsa for Waldenström's Macroglobulinemia
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
- September 7, 2021
- 1 min read
On August 31, 2021, the U.S. Food and Drug Administration (FDA) approved Brukinsa (zanubrutinib) for the treatment of Waldenström's macroglobulinemia (WM).
This approval was based on the ASPEN clinical trial (NCT03053440), a randomized, active-controlled, open-label study in patients with WM harboring MYD88 L265P mutation, divided into two cohorts. Cohort 1 patients (n=201) were randomized 1:1 to Brukinsa (160 mg twice daily) or ibrutinib (420 mg once daily) until disease progression or intolerable adverse effects. Cohort 2 enrolled patients with wild-type MYD88, or unknown MYD88 mutation status (n=26 and n=2, respectively), and received Brukinsa (160 mg twice daily).
The efficacy data supporting this approval were based on criteria established at the 6th International Workshop on Waldenström's Macroglobulinemia, which incorporated response assessments above IRC thresholds and included duration of response as an additional efficacy endpoint.
Results:
In Cohort 1, the Brukinsa arm achieved an objective response rate (ORR) of 77.5% and a 12-month duration of response rate of 94.4%. In Cohort 2, the ORR was 50%.
Safety:
The most common adverse reactions (including laboratory abnormalities, ≥20%) in the Brukinsa arm included neutropenia, upper respiratory tract infection, thrombocytopenia, rash, hemorrhage, musculoskeletal pain, decreased hemoglobin, bruising, diarrhea, pneumonia, and cough.
Recommended dosing: Brukinsa 160 mg orally twice daily or 320 mg once daily.
Source: https://www.cancerit.jp/70053.html
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4